synthego.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $830.14MM
Synthego, founded in 2012 by Paul and Michael Dabrowski, is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms for science at scale. Synthego is setting out to accelerate CRISPR research, a genome engineering technique that could help cure genetic diseases or even bring back woolly mammoths from extinction. Synthego is headquartered in Redwood City, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/17/2022 | Series E | $144.17MM | $xx.xx | $1.3B | Chimera Abu Dhabi, Declaration Partners, Gigafund, Laurion Capital Management, Logos Capital, Moore Strategic Ventures, Perceptive Advisors, Ra Capital Management, Softbank, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
13,371,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Chimera Abu Dhabi, Declaration Partners, Gigafund, Laurion Capital Management, Logos Capital, Moore Strategic Ventures, Perceptive Advisors, Ra Capital Management, Softbank, Wellington Management
|
||||||
08/26/2020 | Series D | $100MM | $xx.xx | $486.63MM | 8vc, Founders Fund, Intel Capital, Menlo Ventures, Ra Capital Management, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
18,925,988
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Founders Fund, Intel Capital, Menlo Ventures, Ra Capital Management, Wellington Management
|
||||||
10/23/2018 | Series C | $116.27MM | $xx.xx | $381.27MM | 8vc, Founders Fund, Menlo Ventures | |
Price per Share
$xx.xx
Shares Outstanding
22,005,928
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Founders Fund, Menlo Ventures
|
||||||
01/04/2017 | Series B-1 | $4.45MM | $xx.xx | $115.78MM | 8vc, Alexandria Equities, Ame Cloud Ventures, Elements Capital, Founders Fund, Menlo Ventures, Os Fund, Scifi Vc, Wi Harper Group, Zhenfund | |
Price per Share
$xx.xx
Shares Outstanding
1,942,877
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexandria Equities, Ame Cloud Ventures, Elements Capital, Founders Fund, Menlo Ventures, Os Fund, Scifi Vc, Wi Harper Group, Zhenfund
|
||||||
01/04/2017 | Series B | $41.88MM | $xx.xx | $115.78MM | 8vc, Alexandria Equities, Ame Cloud Ventures, Elements Capital, Founders Fund, Menlo Ventures, Os Fund, Scifi Vc, Wi Harper Group, Zhenfund | |
Price per Share
$xx.xx
Shares Outstanding
17,369,511
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
8vc, Alexandria Equities, Ame Cloud Ventures, Elements Capital, Founders Fund, Menlo Ventures, Os Fund, Scifi Vc, Wi Harper Group, Zhenfund
|
||||||
07/05/2013 | Series A | $8.3MM | $xx.xx | $33.21MM | Founders Fund, Menlo Ventures, Scifi Vc, Wi Harper Group | |
Price per Share
$xx.xx
Shares Outstanding
9,501,792
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Founders Fund, Menlo Ventures, Scifi Vc, Wi Harper Group
|